[The clinical evaluation of a change in lipid peroxidation in patients with ischemic heart disease and cardiac arrhythmias].
Overall 93 patients suffering from coronary heart disease /CHD/ (without acute myocardial infarction) complicated by cardiac rhythm impairment were followed up. Investigation of lipid peroxidation (LPO) and of the antioxidant system (AOS) in those patients revealed LPO activation and a decrease of the AOS activity both at the moment of arrhythmia and after its arrest, with the highest LPO activation being seen in the hyper- and hypokinetic hemodynamic variants. The experimental studies have demonstrated a reverse relationship between the rise of LPO products in the blood, LPO activation in myocytes and the onset of arrhythmia because of an increase in the density of Na(+)-Ca++ channels of the membrane, accumulation of those ions by the cell, and an increase of the transmembranous potential at rest. Therefore, to prevent and treat cardiac rhythm impairment in CHD patients, it is necessary to administer the blockers of Na(+)-Ca++ channels (etmozin, ethacizine, verapamil and so forth) and antioxidants that raise the reserve capacity of the AOS, including laser therapy.
Olesin
A I
AI
Pavlova
R N
RN
Lobanov
N A
NA
D000328:Adult; D000368:Aged; D000975:Antioxidants; D001145:Arrhythmias, Cardiac / Q000097:blood* / Q000209:etiology / Q000503:physiopathology; D002374:Catalase / Q000097:blood; D003327:Coronary Disease / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D004220:Disulfides / Q000097:blood; D004912:Erythrocytes / Q000201:enzymology; D006439:Hemodynamics; D006801:Humans; D015227:Lipid Peroxidation; D008875:Middle Aged; D010974:Platelet Aggregation; D013438:Sulfhydryl Compounds / Q000097:blood
D000975:Antioxidants; D004220:Disulfides; D013438:Sulfhydryl Compounds; D002374:Catalase
Klinicheskaia otsenka izmeneniia perekisnogo okisleniia lipidov u bol'nykh ishemicheskoĭ bolezn'iu serdtsa s narusheniiami serdechnogo ritma.